ClinicalTrials.gg
Not yet recruitingNCT07024511Updated Jun 17, 2025

Effectiveness of Auricular Acupuncture for Migraine

An interventional study of Auricular acupuncture and Acupuncture in Migraine, sponsored by Universiti Tunku Abdul Rahman. Not yet recruiting at 2 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-06-17.

Sponsored by Universiti Tunku Abdul Rahman · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
156
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 80 studies in Migraine Disorders with a site in China — 34 open to participants now, 40 under way, 10 of them phase 3. Migraine Disorders · China.

Planned enrollment
43rd of 61
156 · median 288
Started
2025
with 12 others
No phase
21 of 80
12 open now
Primary completion
2025-12
later than 6 of 39 live
Registered
63rd of 80
by date

Among the 80 studies in Migraine Disorders with a site in China, this one is the 43rd largest by planned enrollment of the 61 interventional ones that give a count, is one of 13 that started in 2025, is one of 21 with no phase, reaches primary completion later than 6 of the 39 other live ones, and was the 63rd registered.

Migraine Disorders

1,660 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

34 of the 80 studies in Migraine Disorders with a site in China are open now. Recruiting first, the newest first:

29 more — sign in →

All 34 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 80 studies in Migraine Disorders with a site in China, or all of them as a file.
02

Study summary

Migraine is a primary headache disorder characterized by recurrent episodes of moderate to severe pain, frequently accompanied by nausea, photophobia, and phonophobia. It ranks as the third most prevalent medical condition globally and is recognized by the World Health Organization (WHO) as one of the top ten causes of disability worldwide. Migraine presents substantial public health concerns due to its considerable socioeconomic burden and its detrimental impact on individuals' quality of life. Although pharmacological treatments are widely available, their effectiveness is often limited, with many patients experiencing inadequate symptom relief or adverse side effects. Consequently, there has been growing interest in non-pharmacological approaches, particularly acupuncture and auricular therapy, due to their favorable safety profiles and reported efficacy in alleviating migraine symptoms. Auricular therapy, a microsystem of acupuncture applied to specific points on the external ear, has gained popularity for its simplicity, low risk, and therapeutic potential. Despite its increasing clinical use, robust scientific evidence supporting the effectiveness of auricular therapy for migraine remains insufficient, underscoring the need for well-designed clinical studies to validate its therapeutic value.

Read the detailed description

Migraine is a complex and dynamic neurological disorder characterized by fluctuations in attack frequency, duration, severity, and associated symptoms, necessitating timely prevention and effective management strategies. While pharmacological treatments remain the mainstay, their limitations have led to increasing interest in non-pharmacological interventions such as acupuncture. Acupuncture has gained global recognition for its efficacy, particularly in migraine, which is one of the conditions most responsive to this therapy. Supported by strong clinical evidence, acupuncture is considered safe and well-tolerated, with a low incidence of adverse effects. Guidelines for managing primary headache disorders now advocate a range of complementary approaches, including acupuncture, dietary changes, physical activity, and cognitive behavioral therapy which reflecting a paradigm shift towards integrative care. Clinical studies have demonstrated that acupuncture can significantly reduce migraine frequency, shorten attack duration, and alleviate symptom severity. Mechanistic research suggests acupuncture modulates migraine pathophysiology through neuroimmune and neurotransmitter regulation, although further studies are needed to elucidate its molecular effects, particularly beyond the trigeminovascular system. Within Traditional Chinese Medicine, auricular therapy based on stimulating specific points on the external ear aligned with internal organ systems via the "inverted fetus" model offers a simplified, non-invasive modality that activates neural signaling pathways to regulate bodily functions and relieve migraine symptoms. Despite its growing clinical use, further clinical evidence is needed to confirm the therapeutic efficacy and mechanisms of auricular acupuncture in migraine management.

03

Conditions studied

  • Migraine

Keywords

  • Pain
  • Migraine
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed as having migraine with aura and without aura according to the diagnostic criteria specified by the ICHD 3;
  • Aged between 18 and 65 years old;
  • Provided written ;
  • Headache lasting for 4 to 72 hours and occur at least 5 times (untreated or poorly treated);
  • At least 2 out of 4 criteria must be met (unilateral, pulsatile, moderate to severe pain, headache aggravated by daily physical activity, or avoidance of daily activities such as walking or climbing stairs due to headache);
  • At least one of the two criteria must be met (nausea and/or vomiting, photophobia, and fear of sound);
  • At least one fully recoverable premonitory symptom (visual, sensory, speech and/or language, motor, brainstem, retina); Onset time more than 5 minutes; (8) No prophylaxis treatments with acupuncture or drugs in the past 3 months; (9) Written informed consent provided.

Exclusion criteria

Exclusion Criteria:

  • All other diagnoses of chronic, tension-type headache, cluster headache and/or secondary headaches;
  • History of psychotic disorder(s).;
  • Pregnancy or lactation;
  • Severe somatic disorder(s);
  • History of severe organic psychiatric disorder(s);
  • History of other chronic pain condition(s) in the pass 3 months;
  • History of addictive disorder(s);
  • Visual Aura Rating Scale, VARS≥5 score;
  • Taking long-term painkillers for more than 1 month within 3 months.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
156 participants (estimated)

Study arms

  • Experimental
    Auricular acupuncture and acupuncture

    A total of eight treatment sessions will be administered over a period of three weeks, with sessions scheduled approximately every two to three days.

    Other: Auricular acupuncture · Other: Acupuncture

  • Placebo comparator
    Acupuncture and sham auricular acupuncture

    A total of eight treatment sessions will be administered over a period of three weeks, with sessions scheduled approximately every two to three days.

    Other: Acupuncture

Interventions

  • OtherAuricular acupuncture

    Auricular acupuncture

  • OtherAcupuncture

    Acupuncture

06

What researchers measure

Primary outcomes

  1. headache frequency

    The frequency of headaches will be recorded in the form of a headache diary, and doctors will conduct electronic inquiries in WeChat groups every day.

    Time frame: from baseline to 1 month post treatment.

Secondary outcomes

  1. pain severity

    Pain severity is categorized as follows: no pain (0-4 mm), mild pain (5-44 mm), moderate pain (45-74 mm), and severe pain (75-100 mm). The score is determined by measuring the distance (in millimeters) on a 10 cm line between the "no pain" anchor and the patient's mark using a ruler, providing a score range of 0 to 100.

    Time frame: from baseline to 1 month post treatment.

  2. migraine disability

    The Migraine Disability Assessment (MIDAS) questionnaire consists of five questions, each addressing the number of days affected by migraines. The average pain intensity of headaches is rated on a scale from 0 to 10, where 0 indicates no pain and 10 represents the most severe pain.

    Time frame: from baseline to 1 month post treatment

  3. Change of baseline in the mean quality of life as assessed by Migraine-Specific Quality of Life Questionnaire at 1 month

    The Migraine-Specific Quality of Life Questionnaire (MSQ) comprises 3 domains: role function-restrictive (RR), role function-preventive (RP), and emotional function (EF). Each item is scored on a 1-6 scale. Raw dimension scores are computed as a sum of item responses and rescaled from a 0 to 100 scale such that higher scores indicate better quality of life.

    Time frame: from baseline to 1 month post treatment

  4. physical (physical function, pain intensity), mental (depression, anxiety, fatigue, sleep disturbance) and social (ability to participate in social roles and activities).

    1. Patient-Reported Outcomes Measurement Information System (PROMIS) with 7 PROMIS domains including depression, anxiety, physical function, pain interference, fatigue, sleep disturbance, and ability to participate in social roles and activities. The total score of each domain is converted to a standardized T score. 2. In this scale, each item has five response options, with each option scored from 1 to 5 points. For the Anxiety and Depression domains, scoring is reversed: higher scores reflect less severe symptoms. For all other domains, higher scores indicate more severe symptoms or greater impairment. Pain Intensity is rated directly on a 0-10 scale, where 0 represents no pain and 10 represents the worst possible pain.

    Time frame: from baseline to 1 month post treatment

  5. treatment success

    Patients Global Impression of Improvement (PGI-I) is a transition scale that is a single question asking the patient to rate their condition, as compared with how it is prior to before beginning treatment on a scale. This is measured by success , where it is defined as "very much improved" or "much improved".

    Time frame: at immediate post treatment

  6. red blood cell distribution width (RDW)

    RDW testing is a part of blood routine and usually does not require special preparation. Patients do not need to be on an empty stomach. To ensure that blood indicators are not affected by time, all patients will have their blood drawn at 10am on the day after the end of treatment

    Time frame: from baseline to immediate post treatment

  7. adverse side effects

    including bleeding, subcutaneous hemorrhage, hematoma, fainting, serious pain, and local infection

    Time frame: up to 48 hours after each treatment

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2025; primary completion for Dec 2025, 5 months later.

Of 310 non-industry interventional studies with no phase under Migraine Disorders, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 36. This study's planned 5 months is below that.

Counting every sponsor, half of 360 studies reached it within 15 months; a quarter within 7 and three quarters within 33.

How these figures are worked out, and which studies are left out of them.

Registered
May 23, 2025
First posted
Jun 17, 2025
StartEst.
Jul 1, 2025
Primary completionEst.
Dec 31, 2025
CompletionEst.
Dec 31, 2025
Last update
Jun 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07024511
Lead sponsor
Universiti Tunku Abdul Rahman
Responsible party
Foo Chai Nien (Associate Professor, Universiti Tunku Abdul Rahman) — Principal investigator
First posted
Jun 17, 2025
Start date
Jul 1, 2025 (estimated)
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Jun 17, 2025

Study contacts

Chai Nien Foo, PhD
Contact
foocn@utar.edu.my
+60123167252

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion